Elevance Health (ELV) Stock Forecast & Price Target

Compare

2,497 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ELV Analyst Ratings

Strong Buy

12 Buy

3 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Elevance

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ELV Stock 12 Month Forecast

Average Price Target

$494.87

▲(30.20%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $494.87 with a high forecast of $585.00 and a low forecast of $428.00. The average price target represents a 30.20% change from the last price of $380.07.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"366":"$366","421":"$421","476":"$476","531":"$531","586":"$586"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":585,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$585.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":494.87,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$494.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":428,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$428.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[366,421,476,531,586],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,377.05,393.04615384615386,409.0423076923077,425.03846153846155,441.0346153846154,457.03076923076924,473.0269230769231,489.0230769230769,505.0192307692308,521.0153846153846,537.0115384615385,553.0076923076923,569.0038461538461,{"y":585,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,377.05,386.11307692307696,395.17615384615385,404.2392307692308,413.3023076923077,422.36538461538464,431.42846153846153,440.4915384615385,449.5546153846154,458.6176923076923,467.6807692307692,476.74384615384616,485.8069230769231,{"y":494.87,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,377.05,380.96923076923076,384.88846153846157,388.8076923076923,392.7269230769231,396.6461538461539,400.56538461538463,404.4846153846154,408.40384615384613,412.32307692307694,416.2423076923077,420.16153846153844,424.08076923076925,{"y":428,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":530.84,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":528.56,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":526.26,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":550.65,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":507.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":410.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":407.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":367.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":394.05,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":395.22,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":432.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":408.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":377.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$585.00

Average Price Target$494.87

Lowest Price Target$428.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$415

Buy

9.19%

Upside

Reiterated

05/14/25

Elevance Health's overall score of 71 reflects a strong financial foundation with consistent revenue growth and solid profitability, though offset by technical weaknesses and challenges in the Medicaid segment. Valuation is fair, but not compelling enough alone to drive a strong buy recommendation. The earnings call provided positive strategic updates, yet acknowledged ongoing cost pressures. Overall, this positions Elevance Health as a stable investment with areas for improvement, especially in technical momentum and cost management.

Sarah JamesCantor Fitzgerald

Cantor Fitzgerald

$485

Buy

27.61%

Upside

Reiterated

06/04/25

Cantor Fitzgerald Sticks to Their Buy Rating for Elevance Health (ELV)

Ben HendrixRBC Capital

RBC Capital

$478

Buy

25.77%

Upside

Reiterated

06/03/25

RBC Capital Remains a Buy on Elevance Health (ELV)

Andrew Mok CFABarclays

Barclays

$522→$480

Buy

26.29%

Upside

Reiterated

06/03/25

Elevance Health price target lowered to $480 from $522 at BarclaysElevance Health price target lowered to $480 from $522 at Barclays

Stephen BaxterWells Fargo

Wells Fargo

$478

Buy

25.77%

Upside

Reiterated

05/28/25

Wells Fargo Sticks to Their Buy Rating for Elevance Health (ELV)

David S MacdonaldTruist Financial

Truist Financial

$510

Buy

34.19%

Upside

Reiterated

05/01/25

Elevance Health (ELV) Gets a Buy from Truist Financial

David ToungArgus Research

Argus Research

$465

Buy

22.35%

Upside

Reiterated

04/24/25

Argus Research Keeps Their Buy Rating on Elevance Health (ELV)

David WindleyJefferies

Jefferies

$461→$488

Buy

28.40%

Upside

Reiterated

04/23/25

Positive Outlook for Elevance Health: Buy Rating Supported by Medicaid Rate Updates and Strategic Moves

Lance WilkesBernstein

Bernstein

$585

Buy

53.92%

Upside

Reiterated

04/23/25

Bernstein reiterates Outperform on Elevance (ELV); Strong Growth in CarelonBernstein SocGen Group analyst Lance Wilkes reiterated an Outperform rating and $585.00 price target on Elevance (NYSE: ELV).

Ryan LangstonTD Cowen

TD Cowen

$484

Buy

27.34%

Upside

Reiterated

04/23/25

Buy Rating for Elevance Health: Stable Medicaid and Medicare Advantage Outlook with Potential Upside

Whit MayoLeerink Partners

Leerink Partners

$463→$510

Buy

34.19%

Upside

Reiterated

04/22/25

Elevance Health's Growth Potential Justifies Buy Rating Amid Sector Challenges

Joanna GajukBank of America Securities

Bank of America Securities

$465→$480

Hold

26.29%

Upside

Reiterated

04/22/25

Elevance Health: Hold Rating Amid Medicare Cost Pressures and Regulatory Risks

Erin WrightMorgan Stanley

Morgan Stanley

$405→$428

Hold

12.61%

Upside

Reiterated

04/15/25

Elevance Health price target raised to $428 from $405 at Morgan StanleyElevance Health price target raised to $428 from $405 at Morgan Stanley

Michael HaRobert W. Baird

Robert W. Baird

$625→$529

Hold

39.18%

Upside

Downgraded

04/14/25

Elevance Health downgraded to Neutral from Outperform at BairdElevance Health downgraded to Neutral from Outperform at Baird

Ann HynesMizuho Securities

Mizuho Securities

$455→$505

Buy

32.87%

Upside

Reiterated

04/09/25

Elevance Health price target raised to $505 from $455 at MizuhoElevance Health price target raised to $505 from $455 at Mizuho

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$415

Buy

9.19%

Upside

Reiterated

05/14/25

Sarah JamesCantor Fitzgerald

Cantor Fitzgerald

$485

Buy

27.61%

Upside

Reiterated

06/04/25

Cantor Fitzgerald Sticks to Their Buy Rating for Elevance Health (ELV)

Ben HendrixRBC Capital

RBC Capital

$478

Buy

25.77%

Upside

Reiterated

06/03/25

RBC Capital Remains a Buy on Elevance Health (ELV)

Andrew Mok CFABarclays

Barclays

$522→$480

Buy

26.29%

Upside

Reiterated

06/03/25

Elevance Health price target lowered to $480 from $522 at BarclaysElevance Health price target lowered to $480 from $522 at Barclays

Stephen BaxterWells Fargo

Wells Fargo

$478

Buy

25.77%

Upside

Reiterated

05/28/25

Wells Fargo Sticks to Their Buy Rating for Elevance Health (ELV)

David S MacdonaldTruist Financial

Truist Financial

$510

Buy

34.19%

Upside

Reiterated

05/01/25

Elevance Health (ELV) Gets a Buy from Truist Financial

David ToungArgus Research

Argus Research

$465

Buy

22.35%

Upside

Reiterated

04/24/25

Argus Research Keeps Their Buy Rating on Elevance Health (ELV)

David WindleyJefferies

Jefferies

$461→$488

Buy

28.40%

Upside

Reiterated

04/23/25

Positive Outlook for Elevance Health: Buy Rating Supported by Medicaid Rate Updates and Strategic Moves

Lance WilkesBernstein

Bernstein

$585

Buy

53.92%

Upside

Reiterated

04/23/25

Ryan LangstonTD Cowen

TD Cowen

$484

Buy

27.34%

Upside

Reiterated

04/23/25

Buy Rating for Elevance Health: Stable Medicaid and Medicare Advantage Outlook with Potential Upside

Whit MayoLeerink Partners

Leerink Partners

$463→$510

Buy

34.19%

Upside

Reiterated

04/22/25

Elevance Health's Growth Potential Justifies Buy Rating Amid Sector Challenges

Joanna GajukBank of America Securities

Bank of America Securities

$465→$480

Hold

26.29%

Upside

Reiterated

04/22/25

Elevance Health: Hold Rating Amid Medicare Cost Pressures and Regulatory Risks

Erin WrightMorgan Stanley

Morgan Stanley

$405→$428

Hold

12.61%

Upside

Reiterated

04/15/25

Elevance Health price target raised to $428 from $405 at Morgan StanleyElevance Health price target raised to $428 from $405 at Morgan Stanley

Michael HaRobert W. Baird

Robert W. Baird

$625→$529

Hold

39.18%

Upside

Downgraded

04/14/25

Elevance Health downgraded to Neutral from Outperform at BairdElevance Health downgraded to Neutral from Outperform at Baird

Ann HynesMizuho Securities

Mizuho Securities

$455→$505

Buy

32.87%

Upside

Reiterated

04/09/25

Elevance Health price target raised to $505 from $455 at MizuhoElevance Health price target raised to $505 from $455 at Mizuho

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

1 Month

xxx

Success Rate

13/23 ratings generated profit

Average Return

+0.87%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.52% of your transactions generating a profit, with an average return of +0.87% per trade.

3 Months

xxx

Success Rate

22/39 ratings generated profit

Average Return

+0.76%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.41% of your transactions generating a profit, with an average return of +0.76% per trade.

1 Year

A.J. RiceUBS

Success Rate

20/27 ratings generated profit

Average Return

+18.90%

reiterated a buy rating 8 months ago

Copying A.J. Rice's trades and holding each position for 1 Year would result in 74.07% of your transactions generating a profit, with an average return of +18.90% per trade.

2 Years

xxx

Success Rate

24/27 ratings generated profit

Average Return

+44.48%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +44.48% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELV Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ELV has received 25 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ELV average Analyst price target in the past 3 months is 494.87.

Each month's total comprises the sum of three months' worth of ratings.

ELV Financial Forecast

ELV Earnings Forecast

Next quarter’s earnings estimate for ELV is $9.25 with a range of $8.61 to $9.98. The previous quarter’s EPS was $11.97. ELV beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year ELV has Outperformed its overall industry.

ELV Sales Forecast

Next quarter’s sales forecast for ELV is $48.14B with a range of $46.79B to $49.72B. The previous quarter’s sales results were $48.89B. ELV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 57.14% of the time in the same period. In the last calendar year ELV has Outperformed its overall industry.

ELV Stock Forecast FAQ

What is ELV’s average 12-month price target, according to analysts?

Based on analyst ratings, Elevance Health’s 12-month average price target is 494.87.

What is ELV’s upside potential, based on the analysts’ average price target?

Elevance Health has 30.20% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ELV a Buy, Sell or Hold?

Elevance Health has a consensus rating of Strong Buy which is based on 12 buy ratings, 3 hold ratings and 0 sell ratings.

What is Elevance Health’s price target?

The average price target for Elevance Health is 494.87. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $585.00 ,the lowest forecast is $428.00. The average price target represents 30.20% Increase from the current price of $380.07.

What do analysts say about Elevance Health?

Elevance Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of ELV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Elevance Health (ELV) Stock Forecast & Price Target

ELV Analyst Ratings

ELV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Elevance Health

ELV Analyst Recommendation Trends

ELV Financial Forecast

ELV Earnings Forecast

ELV Sales Forecast

ELV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts